Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$23.02M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
173.69%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$442.1K
Q3 2024
Cash
Q3 2024
P/E
-5.119
Nov 13, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $2.368M $20.90K $11.60K
YoY Change 11228.9% 80.17%
% of Gross Profit
Research & Development $1.574M $833.2K $126.5K
YoY Change 88.95% 558.66%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.942M $854.1K $138.1K
YoY Change 361.52% 518.5%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $1.643M
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$13.07M -$854.1K -$138.1K
YoY Change 1430.48% 518.46%
Income Tax
% Of Pretax Income
Net Earnings -$13.07M -$854.1K -$138.1K
YoY Change 1430.4% 518.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$0.03
Diluted Earnings Per Share -$0.45 -$0.03 $0.00

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $1.230K $1.400K $0.00
YoY Change -12.14%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $304.0K $47.30K $0.00
YoY Change 542.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $435.2K $48.70K $0.00
YoY Change 793.7%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.339M
YoY Change
Total Long-Term Assets $4.339M $0.00 $0.00
YoY Change
Total Assets $4.774M $48.70K $0.00
YoY Change
Accounts Payable $707.2K $404.2K $18.70K
YoY Change 74.96% 2061.5%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $101.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.336M $986.0K $138.1K
YoY Change 35.45% 613.98%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Liabilities $1.336M $986.0K $138.1K
YoY Change 35.45% 613.98%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding 27.30M shares 26.83M shares
Diluted Shares Outstanding 29.02M shares 26.83M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $117.85 Million

About Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The company went IPO on 2024-02-09. The firm operates as pre-clinical-stage pharmaceutical company focused on developing TELOMIR-1 small molecule to lengthen the deoxyribonucleic acid’s (DNA) protective telomere caps to affect age reversal. The company selectively affects the processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals Inc Athira Pharma Inc Eli Lilly and Co OptiNose Inc Ventyx Biosciences Inc